A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer

Demin Cai, Xiong Zhang, Hong Wu Chen

Research output: Contribution to journalArticle


Lipid and cholesterol reprogramming are often observed in specific cancer subtypes. We find that triple-negative breast cancers (TNBCs), but not estrogen receptor-positive (ER+) ones, adopt nuclear receptor RAR-related orphan receptor γ (RORγ) as their new master activator of cholesterol biosynthesis program. Its dominant role over sterol regulatory element-binding protein 2 (SREBP2) renders TNBC highly vulnerable to RORγ inhibitors alone or in combination with statins.

Original languageEnglish (US)
Article number1701362
JournalMolecular and Cellular Oncology
Issue number2
StatePublished - Mar 3 2020



  • cholesterol homeostasis
  • chromatin
  • ER-positive breast cancer
  • RORγ
  • SREBP2
  • statins
  • therapy
  • TNBC

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research

Cite this